Key Takeaways
- • Star Therapeutics, a South San Francisco biotechnology company, closed a $200 million private financing, according to Massinvestor.
- • The round was co-led by OrbiMed and Janus Henderson Investors, with participation from a broad group of biotech-focused investors and a leading sovereign wealth fund.
- • Proceeds will fund advancing current preclinical programs into the clinic and expanding the pipeline with additional programs.
- • The financing follows Star's July 2026 acquisition of its subsidiary Vega Therapeutics.
Summary
Star Therapeutics, a biotechnology company based in South San Francisco and focused on discovering and developing therapies for diseases with significant unmet need, announced a $200 million private financing, according to Massinvestor. The round was co-led by OrbiMed and Janus Henderson Investors. Other participants included Agent Capital, Catalio Capital Management, Cormorant Asset Management, New Leaf Venture Partners, NYBC Ventures, RA Capital Management, Redmile, Sofinnova Investments, Soleus Capital, and a leading sovereign wealth fund, though the source does not name the sovereign fund.
The financing follows Star's July 2026 acquisition of its subsidiary Vega Therapeutics. Star said proceeds will support its next-generation pipeline of potential best-in-disease therapies. Specifically, the capital will be used to advance current preclinical programs into the clinic and to expand the pipeline with additional programs.
The announcement provides limited detail on valuation, program specifics, or timelines for clinical entry. Readers seeking those details should refer to Star Therapeutics' own disclosures.
The financing follows Star's July 2026 acquisition of its subsidiary Vega Therapeutics. Star said proceeds will support its next-generation pipeline of potential best-in-disease therapies. Specifically, the capital will be used to advance current preclinical programs into the clinic and to expand the pipeline with additional programs.
The announcement provides limited detail on valuation, program specifics, or timelines for clinical entry. Readers seeking those details should refer to Star Therapeutics' own disclosures.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.